Speaker(s): 

Brendan J. Carry, MD, Medical Director, Multidisciplinary Amyloidosis Clinic, Medical Director, LVAD Program, Heart Institute, Geisinger 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Understand pathophysiology of ATTR-CM and PN.
2. Recognize and diagnosis TTR Amyloidosis.
3. Appreciate the ongoing research and the upcoming treatments for TTR Amyloidosis.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Candice Laubach, MBA, Christa Martin, PhD, Jennifer Nunamaker, Christian Lynch, MPH, Eric Wright, PharmD, MPH, Adam Buchanan, MS, MPH, CGC, and David Rolston, MD, FACP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Dr. Carry has the following disclosures: 

 Speaker bureau/consultant/advisor with Pfizer, Daxor, and Aztra Zeneca.

Speaker Bureau/consultant/advisor/research grant with Alnylam.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None